Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARS Pharmaceuticals, Inc (SPRY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: SPRY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -57.25% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio - | 1Y Target Price 31.6 |
Price to earnings Ratio - | 1Y Target Price 31.6 | ||
Volume (30-day avg) 1411878 | Beta 0.87 | 52 Weeks Range 7.55 - 18.51 | Updated Date 06/19/2025 |
52 Weeks Range 7.55 - 18.51 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.11% | Operating Margin (TTM) -466.29% |
Management Effectiveness
Return on Assets (TTM) -6.1% | Return on Equity (TTM) -6.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1286923755 | Price to Sales(TTM) 16.09 |
Enterprise Value 1286923755 | Price to Sales(TTM) 16.09 | ||
Enterprise Value to Revenue 13.25 | Enterprise Value to EBITDA -9.88 | Shares Outstanding 98213600 | Shares Floating 51755600 |
Shares Outstanding 98213600 | Shares Floating 51755600 | ||
Percent Insiders 21.22 | Percent Institutions 80.3 |
Analyst Ratings
Rating 4.83 | Target Price 31.6 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ARS Pharmaceuticals, Inc
Company Overview
History and Background
Silverback Therapeutics Inc. was founded in 2016. It was a biopharmaceutical company focused on developing therapies for cancer and other diseases. However, in November 2022, Silverback announced a strategic shift, discontinuing its lead program and reducing its workforce. It eventually merged with ARS Pharmaceuticals and ceased to exist as a separate entity.
Core Business Areas
- Immuno-oncology Therapeutics (Historical): Silverback Therapeutics Inc. previously focused on developing immuno-oncology therapies using its ImmunoTAC technology platform. Their main goal was to create tissue-targeted therapies to treat a variety of cancer forms.
Leadership and Structure
Prior to the merger with ARS Pharmaceuticals, Laura Shawver served as Chief Executive Officer. The company had a typical biotech organizational structure with departments focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- SBT6050 (Historical): SBT6050 was Silverback's lead product candidate, a TLR8 agonist linked to a HER2-targeting antibody. It was intended to treat HER2-expressing solid tumors. Clinical trials were underway, but development was discontinued. No market share data is available as the product never reached market. Competitors developing HER2-targeted therapies include Roche (Herceptin, Perjeta, Kadcyla) and Daiichi Sankyo/AstraZeneca (Enhertu).
- SBT6290 (Historical): SBT6290 was a TLR8 agonist conjugated to a molecule targeting Nectin-4, being developed for solid tumors. Similar to SBT6050, it was in early development, with no market share information available. Astellas/Seagen (Padcev) is a major competitor in the Nectin-4 targeted therapy space, although Padcev is not TLR8 based.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry. It focuses on harnessing the body's immune system to fight cancer. This field includes checkpoint inhibitors, cell therapies, oncolytic viruses, and immunomodulatory agents.
Positioning
Silverback Therapeutics Inc. was positioned within the immuno-oncology space as a developer of targeted TLR8 agonists. Its ImmunoTAC platform aimed to deliver TLR8 agonists selectively to tumors, potentially reducing systemic toxicity and improving efficacy. Prior to its merger, the company's competitive advantage would've hinged on differentiated clinical data, but did not reach that point.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology is estimated to be hundreds of billions of dollars annually. Silverback Therapeutics Inc. aimed to capture a portion of this market through its targeted TLR8 agonist technology. As its lead products never made it to market, there's no achieved positioning within the TAM.
Upturn SWOT Analysis
Strengths
- Proprietary ImmunoTAC technology platform (Historical)
- Experienced management team (Historical)
- Strong preclinical data supporting ImmunoTAC approach (Historical)
Weaknesses
- Clinical trial failures (Historical)
- Dependence on a single technology platform (Historical)
- Limited financial resources prior to the merger (Historical)
Opportunities
- Partnerships with larger pharmaceutical companies (Historical)
- Expansion of ImmunoTAC platform to new targets (Historical)
- Potential for combination therapies with other immuno-oncology agents (Historical)
Threats
- Competition from established immuno-oncology therapies
- Clinical trial setbacks
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Seagen (SGEN) - acquired by Pfizer (PFE)
Competitive Landscape
Silverback's competitive advantage hinged on its ImmunoTAC platform, offering targeted delivery of TLR8 agonists. However, its lack of successful clinical trials hindered its ability to compete effectively against established immuno-oncology companies with approved products and larger resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Silverback Therapeutics Inc. experienced initial growth related to its IPO and fundraising. However, clinical trial setbacks led to a decline in its stock price and ultimately the merger.
Future Projections: No longer applicable.
Recent Initiatives: The most recent initiative was the merger with ARS Pharmaceuticals, effectively ending Silverback's independent existence.
Summary
Silverback Therapeutics Inc. was a development-stage biotech company with a novel technology platform. Clinical trial setbacks led to a strategic shift and, ultimately, a merger, rendering its prior business obsolete. The company demonstrated initial promise, but struggled to translate its technology into successful clinical outcomes. Investors faced significant losses due to the company's failure to achieve clinical milestones.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Analyst reports
- Industry publications
Disclaimers:
The information provided is based on historical data and publicly available information. The analysis reflects the company's situation prior to the merger and may not be relevant to current market conditions. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ARS Pharmaceuticals, Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-12-04 | Co-Founder, President, CEO & Director Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://ars-pharma.com |
Full time employees 155 | Website https://ars-pharma.com | ||
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.